|
COPYRIGHT 2005 Voxant Inc.
Original Source: CNBC/DOW JONES BUSINESS VIDEO ANALYST INTERVIEW
JOE KERNEN, CNBC ANCHOR: The other big story, of course, the fallout from that Vioxx verdict and it continues. Merck (MRK) was found liable in the death of a 59-year-old tri-athlete who used Vioxx. A Texas Jury awarded the man`s widow $229 million for pain and suffering and $24 million in actual damages. All of these probably will be reduced. But certainly ominous sign for Merck. The stock plunged on the news, down almost 8 percent. But it is not over.
Merck`s attorney, Jonathan Skidmore, plans to appeal.
(BEGIN VIDEO CLIP)
JONATHAN SKIDMORE, MERCK ATTORNEY: Part of the reason for an appeal is that there still is no reliable scientific evidence in the record, this case that went to the jury, of the link between Vioxx and Mr. Ernst`s death.
(END VIDEO CLIP)
KERNEN: And I guess that is what we`re going to talk a lot about. Joining us live from Stamford, Connecticut, is Barbara Ryan, senior pharmaceutical analyst at Deutsche Bank.
How are you, Barbara? Good to see you.
BARBARA RYAN, SENIOR PHARMACEUTICAL ANALYST, DEUTSCHE BANK: Good morning, Joe. Good to see you, thanks.
KERNEN: Was it proven that Vioxx caused this man`s death, Barbara?
RYAN: Well, I think, you know, that that is a debate that obviously will be heard in a court of appeal. But there was the coroner who stated that it could have been caused by a blood clot that obviously caused a heart attack. I think what really...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
